Avidity Biosciences Inc
RNAM
Clasificación en acciones
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Precio por acción
$71.34
Última sincronización: 2026-03-03
Capitalización bursátil
$9.84B
Cambio (1 día)
0.00%
Cambio (1 año)
-
País
US
Comercio Avidity Biosciences Inc (RNAM)
Categoría
Healthcare
Ratio P/S de Avidity Biosciences Inc (RNAM)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Avidity Biosciences Inc, el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Avidity Biosciences Inc desde 2018 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2025 | 533.36 | -28.29% |
| 2024 | 743.81 | 34.08% |
| 2023 | 554.77 | 35.05% |
| 2022 | 410.78 | 27.30% |
| 2021 | 322.68 | 39.17% |
| 2020 | 231.86 | -80.28% |
| 2019 | 1.18K | -83.65% |
| 2018 | 7.19K | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 41.70 | - |
US
|
|
| 4.19 | - |
AU
|
|
| 4.52 | - |
BE
|
|
| 10.44 | - |
NL
|
